Ciprofloxacin and Xarelto (Rivaroxaban) Co-Administration
Ciprofloxacin can be safely co-administered with rivaroxaban (Xarelto) without dose adjustment, as ciprofloxacin is not a significant inhibitor of the metabolic pathways critical to rivaroxaban clearance.
Drug Interaction Profile
Rivaroxaban is metabolized primarily through CYP3A4 and CYP2J2, and is a substrate of P-glycoprotein (P-gp) and BCRP transporters 1, 2. Clinically significant interactions occur only with drugs that are strong inhibitors of both CYP3A4 AND P-gp simultaneously 1, 3, 1.
Why Ciprofloxacin is Safe
Ciprofloxacin is primarily a CYP1A2 inhibitor, not a CYP3A4 inhibitor 4. The FDA labeling confirms that ciprofloxacin inhibits CYP1A2-mediated metabolism and affects drugs metabolized by this pathway (such as theophylline and caffeine), but does not list it as a CYP3A4 or P-gp inhibitor 4.
Drugs That ARE Contraindicated with Rivaroxaban
The following require avoidance due to dual strong inhibition of CYP3A4 and P-gp 1, 3, 1, 2:
- Azole antifungals: ketoconazole, itraconazole, voriconazole, posaconazole (NOT fluconazole, which is only moderate)
- HIV protease inhibitors: ritonavir, cobicistat
- These drugs increase rivaroxaban exposure by 2.5-fold (AUC) and 1.7-fold (Cmax) 1
Drugs Requiring Caution (But Not Contraindicated)
Moderate inhibitors that affect only CYP3A4 OR only P-gp increase rivaroxaban exposure modestly 1, 3, 1, 5:
- Clarithromycin: 54% increase in rivaroxaban exposure 5
- Erythromycin: 34% increase 5
- Fluconazole: 42% increase 5
These can be used with rivaroxaban but require closer monitoring in patients with renal impairment (CrCl 30-50 mL/min) 3, 2.
Practical Management
No dose adjustment or special monitoring is required when combining ciprofloxacin with rivaroxaban in patients with normal renal function. Standard rivaroxaban dosing applies:
- VTE treatment: 15 mg twice daily for 21 days, then 20 mg once daily 6
- Atrial fibrillation: 20 mg once daily (15 mg if CrCl 15-50 mL/min) 7
- Post-PCI with AF: Various regimens depending on bleeding/ischemic risk 8, 9
Important Caveats
Renal function matters: Both drugs are renally cleared. In patients with CrCl 15-30 mL/min, rivaroxaban dose should already be reduced per indication 10, and ciprofloxacin requires dose adjustment 4.
Bleeding risk: While ciprofloxacin doesn't increase rivaroxaban levels, the combination doesn't reduce bleeding risk. Monitor for bleeding as you would with rivaroxaban alone.
Avoid confusion with other fluoroquinolones: This guidance is specific to ciprofloxacin. Other antibiotics (particularly macrolides like clarithromycin/erythromycin) DO interact significantly 1, 3, 5.